Merck’s Insomnia Agent Gaboxadol Shows Promising Phase II Results
This article was originally published in The Pink Sheet Daily
Executive Summary
The firm has highlighted the GABA-A receptor agonist as a standout result from its recent in-licensing deals.
You may also be interested in...
Merck And Lundbeck Discontinue Gaboxadol Development For Insomnia
Phase III trials for the GABA-A receptor antagonist do not support further development, the firms state.
Merck And Lundbeck Discontinue Gaboxadol Development For Insomnia
Phase III trials for the GABA-A receptor antagonist do not support further development, the firms state.
Merck Gaboxadol Submission Delayed Until Mid-2007
Merck and its partner Lundbeck will not submit an NDA for the sleep aid in the first quarter, as previously planned.